These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31244958)

  • 1. Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.
    Valic MS; Zheng G
    Theranostics; 2019; 9(11):3365-3387. PubMed ID: 31244958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models.
    Valic MS; Halim M; Schimmer P; Zheng G
    J Control Release; 2020 Jul; 323():83-101. PubMed ID: 32278829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interspecies scaling and comparisons in drug development and toxicokinetics.
    Ings RM
    Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.
    Van den Bergh A; Sinha V; Gilissen R; Straetemans R; Wuyts K; Morrison D; Bijnens L; Mackie C
    Clin Pharmacokinet; 2011 Aug; 50(8):505-17. PubMed ID: 21740074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicokinetics, dose-response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives.
    Chen Q; Riviere JE; Lin Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1808. PubMed ID: 36416026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To scale or not to scale: the principles of dose extrapolation.
    Sharma V; McNeill JH
    Br J Pharmacol; 2009 Jul; 157(6):907-21. PubMed ID: 19508398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
    Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.
    Teitelbaum Z; Lave T; Freijer J; Cohen AF
    Clin Pharmacokinet; 2010 Sep; 49(9):619-32. PubMed ID: 20690784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between pharmacokinetics and toxicokinetics.
    Welling PG
    Toxicol Pathol; 1995; 23(2):143-7. PubMed ID: 7569668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and calibration of high-throughput predictions of chemical distribution to tissues.
    Pearce RG; Setzer RW; Davis JL; Wambaugh JF
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):549-565. PubMed ID: 29032447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach.
    Hamidi M; Azadi A; Rafiei P; Ashrafi H
    Crit Rev Ther Drug Carrier Syst; 2013; 30(5):435-67. PubMed ID: 24099328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of volume of distribution at steady state in humans: comparison of different approaches.
    Zou P; Zheng N; Yang Y; Yu LX; Sun D
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):855-72. PubMed ID: 22591253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues related to the use of canines in toxicologic pathology--issues with pharmacokinetics and metabolism.
    Tibbitts J
    Toxicol Pathol; 2003; 31 Suppl():17-24. PubMed ID: 12597427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach.
    Benjamin B; Barman TK; Chaira T; Paliwal JK
    Curr Drug Discov Technol; 2010 Sep; 7(3):143-53. PubMed ID: 20843296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.